NASDAQ:MNTA Momenta Pharmaceuticals (MNTA) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free MNTA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$52.48▼$52.4850-Day Range$52.26▼$52.4952-Week Range$12.21▼$52.53VolumeN/AAverage Volume1.94 million shsMarket Capitalization$6.25 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Momenta Pharmaceuticals alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Momenta Pharmaceuticals Stock (NASDAQ:MNTA)Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.Read More Ad Crypto 101 MediaAltcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!) MNTA Stock News HeadlinesFebruary 28, 2023 | thestreet.comGenoptix, Momenta Shares Headed for GainsMay 25, 2022 | msn.comJohnson & Johnson, Momenta Pharma file lawsuit against Natco, Mylan in USMarch 28, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. May 1, 2022 | thestreet.comEastman Kodak, Rambus: After-Hours TradingAugust 3, 2021 | nasdaq.comMomenta Pharmaceuticals, Inc. Common Stock (MNTA)See More Headlines Receive MNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Momenta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:MNTA CUSIP60877T10 CIK1235010 Webwww.momentapharma.com Phone617-491-9700FaxN/AEmployees131Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,050,000.00 Net Margins-757.61% Pretax MarginN/A Return on Equity-61.44% Return on Assets-45.28% Debt Debt-to-Equity RatioN/A Current Ratio6.38 Quick Ratio6.38 Sales & Book Value Annual Sales$23.87 million Price / Sales261.69 Cash FlowN/A Price / Cash FlowN/A Book Value$4.59 per share Price / Book11.43Miscellaneous Outstanding Shares119,029,000Free FloatN/AMarket Cap$6.25 billion OptionableOptionable Beta1.71 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Craig A. Wheeler (Age 59)Pres, CEO & Exec. Director Dr. Ganesh Venkataraman Kaundinya (Age 52)Co-Founder & Consultant Dr. Santiago Arroyo (Age 59)Chief Medical Officer & Sr. VP of Devel. Mr. Bruce A. Leicher (Age 63)Consultant Mr. Scott M. StorerConsultantKey CompetitorsExelixisNASDAQ:EXELHalozyme TherapeuticsNASDAQ:HALORepligenNASDAQ:RGENNeurocrine BiosciencesNASDAQ:NBIXCRISPR TherapeuticsNASDAQ:CRSPView All Competitors MNTA Stock Analysis - Frequently Asked Questions How were Momenta Pharmaceuticals' earnings last quarter? Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.06. The biotechnology company earned $6.61 million during the quarter, compared to the consensus estimate of $5.84 million. Momenta Pharmaceuticals had a negative trailing twelve-month return on equity of 61.44% and a negative net margin of 757.61%. What other stocks do shareholders of Momenta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Momenta Pharmaceuticals investors own include Exelixis (EXEL), Novavax (NVAX), Gilead Sciences (GILD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Pfizer (PFE), ACADIA Pharmaceuticals (ACAD), ImmunoGen (IMGN) and CRISPR Therapeutics (CRSP). This page (NASDAQ:MNTA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Momenta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.